66 related articles for article (PubMed ID: 15250044)
1. Mechanism of immune response during immunotherapy.
Panelli MC; Nagorsen D; Wang E; Monsurro V; Jin P; Katia Z; Smith K; Ngalame Y; Marincola FM
Yonsei Med J; 2004 Jun; 45 Suppl():15-7. PubMed ID: 15250044
[TBL] [Abstract][Full Text] [Related]
2. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
4. A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization.
Panelli MC; Martin B; Nagorsen D; Wang E; Smith K; Monsurro V; Marincola FM
Cells Tissues Organs; 2004; 177(3):124-31. PubMed ID: 15388986
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
7. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration.
Panelli MC; Wang E; Phan G; Puhlmann M; Miller L; Ohnmacht GA; Klein HG; Marincola FM
Genome Biol; 2002 Jun; 3(7):RESEARCH0035. PubMed ID: 12184809
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
10. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
13. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
[TBL] [Abstract][Full Text] [Related]
14. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
15. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of IL-2.
Sznol M; Parkinson DR
Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
[TBL] [Abstract][Full Text] [Related]
17. T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy.
Willhauck M; Möhler T; Scheibenbogen C; Pawlita M; Brossart P; Schmier JW; Keilholz U
Clin Cancer Res; 1996 Apr; 2(4):767-72. PubMed ID: 9816229
[TBL] [Abstract][Full Text] [Related]
18. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 therapy of cancer-clinical perspectives.
Majidpoor J; Mortezaee K
Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
